{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-26-000010","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.358315+00:00","generated_at":"2026-05-15T09:21:42.912476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026","bullets":["Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.","Cash, equivalents and short-term investments $98.3M as of Dec 31, 2025; expected runway into 2028.","R&D expenses $50.1M, up $25.6M YoY driven by Phase 2 LOTUS trial costs for abdakibart (AVTX-009).","Topline data from Phase 2 abdakibart trial for hidradenitis suppurativa expected in Q2 2026.","G&A expenses $22.9M, up $5.7M primarily from stock-based compensation and headcount additions."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-26-000010","json":"https://secwatch.observer/filing/0001534120-26-000010.json","markdown":"https://secwatch.observer/filing/0001534120-26-000010.md","text":"https://secwatch.observer/filing/0001534120-26-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/0001534120-26-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/avtx-20260323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:21:42.912476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0772b9fb47fcbef211db9700e34a4d3ef83a0bcd","claim":"Avalo Therapeutics, Inc. reported the year ended December 31, 2025 results: net income Net loss was $78.3 million for the year ended December 31, 2025, EPS Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025.","evidence_excerpt":"On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/0001534120-26-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"Net loss was $78.3 million for the year ended December 31, 2025"},{"label":"EPS","value":"Basic and diluted net loss per share was $5.84 for the year-ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}